ONCOSCOPE
REAL-TIME ONCOLOGY LIBRARY

**Stacy Grieve[1], Anna Forsythe[1], Peter Kaufman[2]**

[1]Oncoscope, Miami, FL, USA; [2]The University of Vermont, Miami, FL, USA

**ISPOR Europe 2026**
8-11 November 2026
Vienna, Austria

**HTA338**

# When evidence moves faster than guidelines

## Maintaining synchronization across regulatory, clinical, and HTA milestones in breast cancer (BC)

## BACKGROUND

In rapidly evolving oncology indications, regulatory approvals, guideline updates, conference presentations, and HTA assessments occur on different timelines. Traditional SLRs are updated periodically and may fail to capture pivotal evidence changes when they occur, creating evidence synchronization challenges for market access and HTA planning.

## OBJECTIVES

This study evaluated whether **Oncoscope** Real-Time AI-Assisted Living SLR **(REAL-SLR)** can maintain alignment between evolving evidence and key decision-making milestones in breast cancer.

## METHODS

A **PRISMA-aligned**, continuously-updated Oncoscope REAL-SLR in BC based on a published protocol-driven search strategy was utilized. REAL-SLR systematically identifies and structures the evidence from interventional clinical trials, regulatory approvals, clinical guidelines, and HTA reviews with daily updates. A year-in-review of studies of antibody-drug conjugates (ADCs) published from January 1, 2025 to June 16, 2026 was conducted. Evidence capture and update timelines were compared between REAL-SLR and traditional SLR approaches.

Table1. **Oncoscope REAL-SLR PICOS & JCA mapping**

| PICOS | REAL-SLR PICOS | JCA Mapping |
|---|---|---|
| Patient population | Patients diagnosed with BC at any stage | Same as REAL-SLR PICOS |
| Interventions and Comparators | Any intervention used for the treatment of BC (surgery, radiotherapy, drugs, biologics, cell treatments, vaccines, etc.) | **Therapies involving Antibody Drug Conjugates (ADC)** |
| Outcomes measures | Efficacy (OS, PFS, other progression, response), PROs, safety | Same as REAL-SLR PICOS |
| Study design | RCTs, non-RCTs, single arm, Phase 1, Phase 1/2, Phase 2, Phase 2/3, Phase 3, Phase 4; Pooled analyses of RCTs; ECTs | Same as REAL-SLR PICOS |
| Restrictions | | **Published between January 2025 to June 16 2026** |

## KEY TAKEAWAYS

In breast cancer, evolving evidence and decision-making milestones frequently occur on ASYNCHRONOUS TIMELINES.

REAL-SLR may reduce evidence synchronization risk, improve HTA and market access preparedness, and support timely evidence generation and reimbursement decision-making.

Figure 1. **Continuously updated PRISMA (REAL-SLR framework) in BC (updated June 16, 2026)**




Figure 2. **REAL-SLR evidence capture summary during the study period**




Figure 3. **ADC-related milestones during the study period converged within weeks**




- In **early-stage breast cancer**, two regulatory approvals for trastuzumab deruxtecan for the neoadjuvant and adjuvant setting occurred simultaneously whereas incorporation into US treatment guidelines lagged by approximately one month. During this interval, additional subgroup, safety, QOL and efficacy results became available.
- In **metastatic breast cancer**, 20 phase 2 / phase 3 randomized controlled trials of ADCs were identified. Majority of these (19/20) had data presented in conference abstracts, of which almost half (9/19) were published at ASCO 2026 and ESMO Breast 2026.




Figure 4. **REAL-SLR reduced evidence synchronization delays**




View all Oncoscope posters at ISPOR Europe 2026

### ABBREVIATIONS

**ADC**, antibody-drug conjugate; **ASCO**, American Society of Clinical Oncology; **BC**, breast cancer; **Dato-DXd**, datopotamab deruxtecan; **ECTs**, externally controlled trials; **ESMO**, European Society for Medical Oncology; **FDA**, US Food and Drug Administration; **HTA**, health technology assessment; **JCA**, Joint Clinical Assessment; **mBC**, metastatic breast cancer; **NCCN**, National Comprehensive Cancer Network; **OS**, overall survival; **P,** pertuzumab; **Pembro,** pembrolizumab; **PFS**, progression-free survival; **PICO(S)**, population, intervention, comparator, outcomes (study design); **PRISMA**, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; **PRO**, patient-reported outcome; **QoL**, quality of life; **RCT**, randomized controlled trial; **REAL-SLR**, Real-Time AI-Assisted Living Systematic Literature Review; **SG**, sacituzumab govitecan; **SLR**, systematic literature review; **T-DXd**, trastuzumab deruxtecan; **US**, United States.